Scientists tested the safety and efficacy of chimeric antigen receptor T cell therapy in refractory/relapsed acute myeloid leukemia .
[Clinical Cancer Research]
6445212
{6445212:M6DFZAKZ}
apa
50
1
161036
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-422aa7694e26f873796925c43260b877%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22M6DFZAKZ%22%2C%22library%22%3A%7B%22id%22%3A6445212%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Zhang%20et%20al.%22%2C%22parsedDate%22%3A%222021-01-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EZhang%2C%20H.%2C%20Wang%2C%20P.%2C%20Li%2C%20Z.%2C%20He%2C%20Y.%2C%20Gan%2C%20W.%2C%20%26amp%3B%20Jiang%2C%20H.%20%282021%29.%20Anti-CLL1%20chimeric%20antigen%20receptor%20T%20cell%20therapy%20in%20children%20with%20relapsed%5C%2Frefractory%20acute%20myeloid%20leukemia.%20%3Ci%3EClinical%20Cancer%20Research%3C%5C%2Fi%3E.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F1078-0432.CCR-20-4543%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F1078-0432.CCR-20-4543%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6445212%26amp%3Bitem_key%3DM6DFZAKZ%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Anti-CLL1%20chimeric%20antigen%20receptor%20T%20cell%20therapy%20in%20children%20with%20relapsed%5C%2Frefractory%20acute%20myeloid%20leukemia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hui%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pengfei%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zhuoyan%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yingyi%22%2C%22lastName%22%3A%22He%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wenting%22%2C%22lastName%22%3A%22Gan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hua%22%2C%22lastName%22%3A%22Jiang%22%7D%5D%2C%22abstractNote%22%3A%22Purpose%3A%20The%20survival%20rate%20of%20children%20with%20refractory%5C%2Frelapsed%20acute%20myeloid%20leukemia%20%28R%5C%2FR-AML%29%20by%20salvage%20chemotherapy%20is%20minimal.%20Treatment%20with%20chimeric%20antigen%20receptor%20T%20cells%20%28CAR-T%29%20has%20emerged%20as%20a%20novel%20therapy%20to%20improve%20malignancies%20treatment.%20C-type%20lectin-like%20molecule%201%20%28CLL1%29%20is%20highly%20expressed%20on%20AML%20leukemia%20stem%20cells%2C%20blast%20cells%2C%20and%20monocytes%2C%20but%20not%20on%20normal%20hematopoietic%20stem%20cells%2C%20indicating%20the%20therapeutic%20potential%20of%20anti-CLL1%20CAR-T%20in%20AML%20treatment.%20This%20study%20aimed%20to%20test%20the%20safety%20and%20efficacy%20of%20CAR-T%20cell%20therapy%20in%20R%5C%2FR-AML.%20Experimental%20Design%3A%20Four%20pediatric%20patients%20with%20R%5C%2FR-AML%20were%20enrolled%20in%20the%20ongoing%20phase%201%5C%2F2%20anti-CLL1%20CAR-T%20cell%20therapy%20trial.%20The%20CAR%20design%20was%20based%20on%20an%20apoptosis-inducing%20gene%2C%20FKBP-caspase%209%2C%20to%20establish%20a%20safer%20CAR%20%284S-CAR%29%20application.%20Anti-CLL1%20CAR%20was%20transduced%20into%20peripheral%20blood%20mononuclear%20cells%20of%20the%20patients%20via%20lentivector%204SCAR%2C%20followed%20by%20infusion%20into%20the%20recipients%20after%20lymphodepletion%20chemotherapy.%20Cytokine%20release%20syndrome%2C%20immune%20effector%20cell-associated%20neurotoxicity%20syndrome%2C%20and%20other%20adverse%20events%20were%20documented.%20Treatment%20response%20was%20evaluated%20by%20morphology%20and%20flow%20cytometry-based%20minimal%20residual%20disease%20assays.%20Results%3A%20Three%20R%5C%2FR-AML%20patients%20achieved%20complete%20remission%20and%20minimal%20residual%20disease%20negativity%2C%20while%20the%20other%20patient%20remained%20alive%20for%20five%20months.%20All%20these%20patients%20experienced%20low-grade%20and%20manageable%20adverse%20events.%20Conclusions%3A%20Based%20on%20our%20single-institution%20experience%2C%20autologous%20anti-CLL1%20CAR-T%20cell%20therapy%20has%20the%20potential%20to%20be%20a%20safe%20and%20efficient%20alternative%20treatment%20for%20children%20with%20R%5C%2FR-AML%2C%20and%20therefore%20requires%20further%20investigation.%22%2C%22date%22%3A%222021%5C%2F01%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1158%5C%2F1078-0432.CCR-20-4543%22%2C%22ISSN%22%3A%221078-0432%2C%201557-3265%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fclincancerres.aacrjournals.org%5C%2Fcontent%5C%2Fearly%5C%2F2021%5C%2F04%5C%2F07%5C%2F1078-0432.CCR-20-4543%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-09T16%3A35%3A52Z%22%7D%7D%5D%7D
Zhang, H., Wang, P., Li, Z., He, Y., Gan, W., & Jiang, H. (2021). Anti-CLL1 chimeric antigen receptor T cell therapy in children with relapsed/refractory acute myeloid leukemia. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-20-4543 Cite
